ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TRLS Trellus Health Plc

1.65
0.00 (0.00%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Trellus Health Plc LSE:TRLS London Ordinary Share GB00BNNFM402 ORD GBP0.0006
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.65 1.50 1.80 1.65 1.65 1.65 0.00 07:40:53
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices Of Medical Doctors 19k -6.34M -0.0392 -0.42 2.66M

Trellus Health PLC Grant of Share Options

05/03/2024 7:00am

RNS Regulatory News


RNS Number : 5488F
Trellus Health PLC
05 March 2024
 



 

Trellus Health plc

("Trellus Health" or the "Company")

 

Grant of Share Options

 

LONDON, U.K. AND NEW YORK, U.S. (5 March 2024). Trellus Health plc (AIM: TRLS), a health services company delivering innovative, scientifically validated programs and technologies that facilitate the comprehensive management of chronic conditions, improving health outcomes whilst managing costs of care, announces that the Board has granted options over a total of 2,000,000 ordinary shares of £0.0006 each in the capital of the Company (the "Share Options") to the following PDMRs:

 

Name

Position

Options granted




Marla Dubinsky

Chief Executive Officer

500,000

Joy Bessenger

Chief Financial Officer (non-Director)

1,500,000

 

The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of 14p per ordinary share.  

 

Both of these options would vest and become exercisable as to one third in 12 months of the grant date and in eight (8) equal quarterly instalments thereafter, of which the first instalment shall vest three months after the first anniversary of the grant date and the eighth shall vest 36 months after the grant date, save that the option shall be exercisable in full in connection with a Change of Control.

 

For further information please contact:

 

Trellus Health plc

https://trellushealth.com/

Dr. Marla Dubinsky, CEO and Co-Founder

Via Walbrook PR

Dr. Daniel Mahony, Chairman




Singer Capital Markets (Nominated Adviser and Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Jen Boorer




Walbrook PR

Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com

Paul McManus / Sam Allen / Phillip Marriage

Mob: +44 (0)7980 541 893 / (0)7502 558 258/ (0)7867 984 082

 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health (AIM: TRLS) is the first clinically-proven digital health company targeting the intersection of chronic illness and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate™, a whole-person technology-enhanced experience that empowers individuals to master their health and results in relieving disease burden, building self-management skills and promoting positive health behaviours that improve outcomes and enables thriving in the face of a chronic condition.

 

The Company's proven whole person approach recognizes the interconnectedness of various aspects of a person's life and aims to address the whole spectrum of factors that influence behaviour. By looking at all aspects of an individual, the Company not only treats symptoms but promotes comprehensive well-being and human flourishing. Trellus Health addresses behavior change with a combination of technology, interventions, education, and support mechanisms designed to empower individuals to take an active role in managing and mastering their health and sustain positive lifestyle modifications and resilient health-related behaviours. By bringing these components together, Trellus Elevate™ promotes positive change in individual behaviours and enhancing provider quality metrics in a way that aligns with value-based care. Our approach enables better health outcomes in a member-centric, personalized and holistic comprehensive solution.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and healing both the physical and emotional impacts of IBD and IBS and have been innovators for whole person healthcare for a combined 50 years.

 

The Company is initially focusing on chronic costly GI conditions that have high mental health burden, like inflammatory bowel disease ("IBD") which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis and Irritable Bowel Syndrome ("IBS"). Given the common emotional and mental health struggles often experienced by individuals suffering from a variety of chronic conditions, Trellus Health considers its approach to be agnostic, having potential utility and demand across many conditions.

 

The Trellus Elevate™ program incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than seven years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers and health systems. Patients with IBD managed with the proprietary resilience methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program which is a major indicator of improved health outcomes1.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

 

1 Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258)

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Marla Dubinsky

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer (Director)

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Trellus Health plc

b)

 

LEI

 

2138002FHWJSR8YKP295

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Options over ordinary shares of £0.0006 each in the Company



Identification code

GB00BNNFM402



b)

 

Nature of the transaction

 

 

Grant of options over shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




£0.14

500,000







d)

 

Aggregated information

 

 

 

 



- Aggregated volume

N/A



- Price

N/A



e)

 

Date of the transaction

 

 

4 March 2024

f)

 

Place of the transaction

 

 

Outside of trading venue - off market

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Joy Bessenger

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer (Not a director)

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Trellus Health plc

b)

 

LEI

 

2138002FHWJSR8YKP295

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Options over ordinary shares of £0.0006 each in the Company



Identification code

GB00BNNFM402



b)

 

Nature of the transaction

 

 

Grant of options over shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




£0.14

1,500,000







d)

 

Aggregated information

 

 

 

 



- Aggregated volume

N/A



- Price

N/A



e)

 

Date of the transaction

 

 

4 March 2024

f)

 

Place of the transaction

 

 

Outside of trading venue - off market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHJIMTTMTTMTFI

1 Year Trellus Health Chart

1 Year Trellus Health Chart

1 Month Trellus Health Chart

1 Month Trellus Health Chart

Your Recent History

Delayed Upgrade Clock